evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

12 questions · 14 findings · 2 reviews · Kidney and Transplant · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 35.7%Moderate 4 · 28.6%High 3 · 21.4%

CERA vs other ESA

Final Hb · patients with the anaemia of end‐stage kidney disease undergoing dialysis
3 findings from 1 review

CERA vs other ESA

All‐cause mortality: CERA every 2 weeks versus rHuEPO · patients with the anaemia of end‐stage kidney disease undergoing dialysis

CERA showed no clear difference in all‐cause mortality: CERA every 2 weeks versus rHuEPO compared with other ESA (moderate certainty).

1 finding from 1 review

CERA vs other ESA

Transfusions: CERA every 2 weeks versus rHuEPO · patients with the anaemia of end‐stage kidney disease undergoing dialysis

CERA showed no clear difference in transfusions: CERA every 2 weeks versus rHuEPO compared with other ESA (moderate certainty).

1 finding from 1 review

CERA vs other ESA

Adverse events: hypertension · patients with the anaemia of end‐stage kidney disease undergoing dialysis

CERA showed no clear difference in numbers of adverse events due to hypertension: CERA every 2 weeks… compared with other ESA (high certainty).

1 finding from 1 review

CERA vs other ESA

Numbers of adverse events due to access thrombosis · patients with the anaemia of end‐stage kidney disease undergoing dialysis

CERA showed no clear difference in numbers of adverse events due to access thrombosis: CERA every 2… compared with other ESA (moderate certainty).

1 finding from 1 review